Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Intracorporeal Lithotripsy Treatment & Management

  • Author: Michael Grasso, III, MD; Chief Editor: Bradley Fields Schwartz, DO, FACS  more...
 
Updated: Sep 11, 2013
 

Surgical Therapy

Ultrasonic lithotripsy

See the list below:

  • This used most commonly via a percutaneously placed rigid endoscope.
  • This form of endoscopic lithotripsy requires a straight working channel because power is decreased significantly with any endoscope deflection.
  • In addition, ultrasonic lithotripsy is used most commonly to manage infectious calculi in which the hollow core probe and suction can simultaneously fragment and evacuate stone particles.
    Treatment was based on percutaneous access and rig Treatment was based on percutaneous access and rigid endoscopic lithotripsy to clear the central stone burden with the hollow core ultrasonic lithotripter. On this image, a flexible nephroscope and holmium laser were also used to address portions of the stone burden inaccessible to the rigid equipment.

Electrohydraulic lithotripsy

See the list below:

  • These probes are based on sparking an electrode on a wire cable that can be placed through rigid or flexible endoscopes.
  • These fragment stones into extractable pieces but are less efficient than holmium:YAG lasers on the hardest calculi.
  • In most centers, this form of endoscopic lithotrite has been replaced and/or supplemented by holmium lasers.

Mechanical and ballistic lithotripsy

See the list below:

  • These devices are powerful and based on pneumatically driven projectiles that strike a metallic probe placed endoscopically on a calculus. Commonly, the created fragments require extraction with either an endoscopic basket or grasper.
  • These devices work best when they are used through a rigid endoscope, and they can be associated with stone migration during treatment.
  • The flexible pneumatic lithotripsy probe was developed to complement flexible endoscopes. Tip displacement and fragmentation ability of the probe have been shown to be inversely related to the degree of active deflection of the ureteroscope; thus, this has minimal clinical usefulness.

Laser lithotripsy

See the list below:

  • The pulsed-dye laser was the first commonly used laser lithotripter.
  • When using a light energy of 504 nm delivered in a pulsatile fashion through quartz fibers, calculi are fragmented.
  • A photo-acoustic effect forms plasma between the tip of the fiber and the calculus, fragmenting stones along fracture planes.
  • The deliverable energy is limited by fiber diameter, with the smallest fibers able to deliver only 80 MJ, which is often insufficient to fragment the hardest stones. In addition, this laser energy has little effect on cystine calculi; 504 nm of light energy passes through this crystal rather than creating the aforementioned plasma on the surface.
  • Various lasers used in lithotripsy include the following:
    • Holmium:YAG laser
      • The holmium:YAG laser is one of the most commonly used lasers and has been universally accepted as the standard for intracorporeal lithotripsy. Multiple recent studies have demonstrated that holmium:YAG laser lithotripsy is superior to electrohydraulic lithotripsy, ultrasonic lithotripsy, and pneumolithotripsy in terms of stone fragmentation and complications.
      • Using 2150-nm light energy in a pulsatile fashion, this thermal laser produces a vaporization bubble at the tip of low–water-density quartz fibers. Even with the small 150- to 200-µm fibers, the energy delivered is sufficient to fragment all types of urinary stones into fine dust and small pieces that can then pass easily through the urinary tract. Therefore, hard stones in difficult locations (eg, lower-pole calyx) can be treated using a small-diameter fiber that is easily deflected with the ureteroscope.
      • Holmium laser energy is rapidly absorbed by water, creating a vaporization bubble that has minimal effects on adjacent tissue (2-3 mm from the fiber tip). These qualities result in minimal adjacent tissue trauma. However, direct contact with tissue should be avoided unless tissue resection is planned. In addition, sufficient cooling irrigant through the endoscope should be used to prevent adjacent thermal soft-tissue effects.
      • Holmium laser lithotripsy is more effective than other endoscopic lithotrites for large and complex stone burdens composed of uric acid or cystine.
    • Frequency-doubled, double-pulse neodymium:YAG (FREDDY) laser
      • The FREDDY laser is a neodymium:YAG double-pulse laser.
      • Recent work in Europe has shown that the FREDDY laser is inferior to the holmium:YAG laser in lithotripsy. Whereas the holmium:YAG laser is controlled via a distal tip vaporization bubble that creates acoustic percussion waves that destabilize and fragment stones, neodymium:YAG, even when pulsed, is a high-temperature laser with limited fragmentation capabilities for hard stones and causes significantly greater stone retropulsion. In addition, the FREDDY laser is less versatile and is unable to treat urinary-tissue lesions.[3]
    • The erbium:YAG laser and the thulium:YAG laser are two newly developed lasers being tested in clinical and in vitro trials to improve the efficiency of stone lithotripsy in the future. Fiber delivery for the both lasers is still in its infancy.[4, 5]
    • The video below depicts ureteroscopy and holmium laser lithotripsy.
      Ureteroscopy and laser lithotripsy. Video courtesy of Dennis G Lusaya, MD, and Edgar V Lerma, MD.
Next

Intraoperative Details

Endoscopes: Please refer to the Medscape Reference article Ureteroscopy.

Bladder stones

Rigid, continuous-flow cystoscopic equipment is preferred to treat bladder stones. In addition, a large-caliber resectoscope sheath and laser bridge is a very efficient means of delivering the 1000-µm holmium laser fiber. The larger laser fiber produces a sizable vaporization bubble in saline irrigant, allowing the surgeon to sculpt stone into dust rapidly, while the large sheath keeps the operating field clear be facilitating evacuation of the created debris.

Ureteral stones

Distal ureteral stones are addressed with semirigid endoscopes ranging in diameter from 4.5F-9F. These fiberoptic-based endoscopes can be angled approximately 30° while maintaining clear optical images. Many of the endoscopes are based on a 2-channel system. This allows the surgeon to simultaneously use both an endoscopic lithotrite and basket or grasper. This is particularly useful when a stone is mobile in a dilated ureter. In this case, a basket, or Stone Cone device, can be used to prevent stone migration while the laser is used to sculpt the stone into an extractable core fragment.

Proximal ureteral stones are frequently treated with actively deflectable flexible ureteroscopes. These endoscopes are most commonly smaller than or equal to 8.5F in diameter and have only a single working channel. The smallest-diameter lithotrites are used through these endoscopes. One operative strategy with mobile stones in the proximal ureter is to position the patient in the Trendelenburg prior to endoscopic manipulation. If proximal stone migration is noted during endoscopic lithotripsy, the flexible endoscope can follow the stone into an upper- or middle-pole calyx, where it is more stable and can fragment quickly with the laser lithotripter.

Renal stones

Retrograde ureteroscopic treatment of intrarenal calculi is performed with actively deflectable flexible ureteroscopes. The smallest-diameter lithotripsy probes (eg, 200-µm laser fiber, 1.4F EHL probe) are required to treat lower-pole calyceal calculi.

Percutaneous nephrostolithotomy is performed with both rigid and flexible endoscopes. Rigid nephroscopes usually have offset lens systems to facilitate the straight ultrasonic lithotripsy probes. These probes are hollow and allow for simultaneous evacuation of debris during fragmentation. This is useful for treating infectious, matrix-based, staghorn calculi.

Staghorn renal calculus is noted on plain radiogra Staghorn renal calculus is noted on plain radiograph of the abdomen.

Flexible nephroscopy is usually performed after the rigid nephroscope and ultrasonic lithotripter have cleared a large, central, stone burden and peripheral calyceal calculi remain. The rigid endoscope is often prohibited access to these peripheral stones, while the flexible 15-18F nephroscope can direct a lithotrite safely onto them. The same flexible lithotripsy probes used for ureteroscopic lithotripsy are passed through the large (>6F) working channel. Nitinol basket extractors are also commonly passed through the flexible nephroscope to extract the remaining small stones and fragments.

All endoscopic lithotrites are used under direct vision through the working channel of an endoscope.

Endoscopic baskets can also be used, most often through a dual-channel rigid endoscope, to stabilize a mobile stone during fragmentation.

Take care when using the holmium:YAG laser in this setting because the laser can easily damage the wires of the basket. Basket fragmentation may lead to foreign bodies within the urinary collection system.

Ureteropyeloscopic treatment of large upper urinary tract calculi

Ureteroscopic treatment of large, noninfected upper urinary tract calculi was first described in 1998 in patients with comorbidities prohibiting percutaneous nephrostolithotomy, who were accrued and treated with retrograde endoscopic techniques.[6] The most recent series was based on 145 patients with 164 stone burdens in excess of 2 cm in diameter, including 36 partial staghorn calculi.[7] The stone-free rate at 3 months was 87%, with an average of 1.6 procedures per patient with minimal complications.

Technically, the procedure begins in a similar fashion to any flexible ureteropyeloscopic procedure. The flexible ureteroscope and laser lithotripter are used to fragment the calculus into fine dust and small residual passable debris smaller than 3 mm. A 14F Foley catheter is placed transurethrally next to the flexible ureteroscope to maintain continuous bladder drainage during the procedure.

Ureteroscopic fragmentation continues until the endoscopic field of view is obscured by dust or debris. All patients are counseled that second-stage ureteroscopy may be required to clear the stone burden. At the conclusion of endoscopic lithotripsy, large-caliber ureteral stents (8-10F) are used to maximize drainage and to passively dilate the ureter overtime, which ultimately helps clear stone debris.

Most importantly, patients with infectious struvite calculi or infected stones are poor candidates and should not be offered this treatment, in that there is a higher risk of perioperative infectious complications. Additionally, residual infectious stone debris may act as a nidus for stone regrowth and future infections. These patients should undergo a percutaneous nephrostolithotomy unless contraindicated.

Previous
Next

Postoperative Details

Internal ureteral stents are often placed after ureteroscopic lithotripsy to help facilitate healing and to ensure drainage, particularly if vigorous therapeutic maneuvers were performed. Internal stents may minimize the risks of urinomas (collections of urine outside the urinary collecting system) and/or ureteral strictures after traumatic endoscopy.

Internal ureteral stents commonly cause lower urinary tract symptoms, which include urinary frequency, urgency, and mild-to-moderate transient hematuria.

The ureteral stents are removed after a period of healing, ranging from a few days to 6-8 weeks, depending on the complexity of the treatment. Stents are usually removed in the office with either an attached nylon suture left through the urethra postoperatively or cystoscopically.

Patients are discharged on oral antibiotics, analgesics, and, occasionally, anticholinergic medication to decrease symptoms associated with the ureteral stent. Antibiotics are commonly used to eliminate any bacteriuria after all tubes have been removed.

Previous
Next

Follow-up

For excellent patient education resources, see eMedicineHealth's patient education articles Kidney Stones and Intravenous Pyelogram.

Previous
Next

Complications

The complications of intracorporeal lithotripsy include problems associated with the endoscopy (potentially, trauma to the urinary tract) and the specific problems created by incomplete stone fragmentation and incomplete fragment elimination.

Incomplete and/or inadequate pulverization of the stones occasionally occurs with all types of lithotripsy. The residual fragments can lead to renal or ureteral colic and secondary procedures.

Previous
Next

Outcome and Prognosis

The endpoint of endoscopic lithotripsy has changed based on new technology. Stone extraction was once commonly used; today, however, devices such as the holmium laser allow the surgeon to safely convert the stone burden to fine particulate debris. This debris is partially irrigated from the collecting system during the procedure or allowed to pass over time.

  • Studies indicate that holmium:YAG lithotripsy is associated with shorter operative time and postoperative hospitalization period than lithoclast lithotripsy for ureteral stones. Data also suggest that holmium:YAG lithotripsy is safe and more effective than lithoclast lithotripsy, with significantly better immediate stone-free rates.
  • The holmium:YAG laser lithotripter can fragment and destroy all compositions of stone. The stone-free rate for ureteral stones approaches 100%. The overall success rate for ureteroscopic treatment of renal stones varies from 75-92%. Complications are rare and minimal when used with the current technique.

Ultrasonic lithotriptors used only through rigid endoscopes provide high fragmentation rates (97-100%) and stone-free rates (94%). Limitations are based primarily on failure of endoscopic access, since this class of lithotrite cannot be deflected significantly and is thus not complementary with semirigid or actively deflectable flexible ureteroscopes.

Previous
Next

Future and Controversies

Traditional open surgical lithotomy procedures have been replaced by extracorporeal, intracorporeal, and percutaneous lithotripsy. Extracorporeal lithotripsy is the least invasive method for eliminating stones, but it has a relatively high failure rate with large stones, obstructing stones, cystine stones, and other complex stones. Intracorporeal lithotripsy is minimally invasive and yields high success rates with most ureteral stones and renal stones. The holmium:YAG laser is currently the most effective and widely used laser available today. Current studies are investigating newer lasers and devices to continually improve the efficiency, cost, and visualization of stone fragmentation via an endoscopic approach.

Controversy still exists about the preferred endoscopic approach, percutaneously through the kidney versus ureteroscopically. The preferred approach is the one that, in the hands of the operator, offers the greatest chance of rendering the patient stone-free with the least morbidity and expense. Therefore, for most urologists, the preferred approach is strongly influenced by the number, size, location, and probable composition of the stone(s) and by the body habitus of the patient.

Previous
 
Contributor Information and Disclosures
Author

Michael Grasso, III, MD Professor and Vice Chairman, Department of Urology, New York Medical College; Director, Living Related Kidney Transplantation, Westchester Medical Center; Director of Endourology, Lenox Hill Hospital

Michael Grasso, III, MD is a member of the following medical societies: Medical Society of the State of New York, National Kidney Foundation, Society of Laparoendoscopic Surgeons, Societe Internationale d'Urologie (International Society of Urology), American Medical Association, American Urological Association, Endourological Society

Disclosure: Received consulting fee from Karl Storz Endoscopy for consulting.

Coauthor(s)

Andrew Ira Fishman, MD Assistant Professor, Department of Urology, New York Medical College

Andrew Ira Fishman, MD is a member of the following medical societies: American Medical Association, American Urological Association

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Chief Editor

Bradley Fields Schwartz, DO, FACS Professor of Urology, Director, Center for Laparoscopy and Endourology, Department of Surgery, Southern Illinois University School of Medicine

Bradley Fields Schwartz, DO, FACS is a member of the following medical societies: American College of Surgeons, Society of Laparoendoscopic Surgeons, Society of University Urologists, Association of Military Osteopathic Physicians and Surgeons, American Urological Association, Endourological Society

Disclosure: Nothing to disclose.

Additional Contributors

Erik T Goluboff, MD Professor, Department of Urology, College of Physicians and Surgeons, Columbia University College of Physicians and Surgeons; Director of Urology, Allen Pavilion, New York Presbyterian Hospital

Erik T Goluboff, MD is a member of the following medical societies: Alpha Omega Alpha, American Medical Association, American Urological Association, Medical Society of the State of New York, New York Academy of Medicine, Phi Beta Kappa, Society for Basic Urologic Research

Disclosure: Nothing to disclose.

Acknowledgements

Keith T Tracy, MD Resident Physician, Department of Urology, New York Medical College, Westchester Medical Center

Keith T Tracy, MD is a member of the following medical societies: Alpha Omega Alpha, American Medical Association, and American Urological Association

Disclosure: Nothing to disclose.

Acknowledgments

Medscape Reference thanks Dennis G Lusaya, MD, Associate Professor II, Department of Surgery (Urology), University of Santo Tomas; Head of Urology Unit, Benavides Cancer Institute, University of Santo Tomas Hospital; Chief of Urologic Oncology, St Luke’s Medical Center Global City, Philippines, for the video contribution to this article.

Medscape Reference also thanks Edgar V Lerma, MD, FACP, FASN, FAHA, Clinical Associate Professor of Medicine, Section of Nephrology, Department of Medicine, University of Illinois at Chicago College of Medicine; Research Director, Internal Medicine Training Program, Advocate Christ Medical Center; Consulting Staff, Associates in Nephrology, SC, for his assistance with the video contribution to this article.

References
  1. Johnson DE, Cromeens DM, Price RE. Use of the holmium:YAG laser in urology. Lasers Surg Med. 1992. 12(4):353-63. [Medline].

  2. Matsuoka K, Iida S, Nakanami M, et al. Holmium: yttrium-aluminum-garnet laser for endoscopic lithotripsy. Urology. 1995 Jun. 45(6):947-52. [Medline].

  3. Dubosq F, Pasqui F, Girard F, et al. Endoscopic lithotripsy and the FREDDY laser: initial experience. J Endourol. 2006 May. 20(5):296-9. [Medline].

  4. Kang HW, Lee H, Teichman JM, et al. Comparison of erbium:YAG versus holmium:YAG lithotripsy. J Urol. 2006. 175 (Suppl 4):574.

  5. Marks AJ, Teichman JM. Lasers in clinical urology: state of the art and new horizons. World J Urol. 2007 Jun. 25(3):227-33. [Medline].

  6. Grasso M, Conlin M, Bagley D. Retrograde ureteropyeloscopic treatment of 2 cm. or greater upper urinary tract and minor Staghorn calculi. J Urol. 1998 Aug. 160(2):346-51. [Medline].

  7. Cohen J, Cohen S, Grasso M. Ureteropyeloscopic treatment of large, complex intrarenal and proximal ureteral calculi. BJU Int. 2013 Mar. 111(3 Pt B):E127-31. [Medline].

  8. Auge BK, Sekula JJ, Springhart WP, et al. In vitro comparison of fragmentation efficiency of flexible pneumatic lithotripsy using 2 flexible ureteroscopes. J Urol. 2004 Sep. 172(3):967-70. [Medline].

  9. Beaghler M, Poon M, Ruckle H, et al. Complications employing the holmium:YAG laser. J Endourol. 1998 Dec. 12(6):533-5. [Medline].

  10. Beiko DT, Denstedt JD. Advances in ureterorenoscopy. Urol Clin North Am. 2007 Aug. 34(3):397-408. [Medline].

  11. Bierkens AF, Hendrikx AJ, De La Rosette JJ, et al. Treatment of mid- and lower ureteric calculi: extracorporeal shock-wave lithotripsy vs laser ureteroscopy. A comparison of costs, morbidity and effectiveness. Br J Urol. 1998 Jan. 81(1):31-5. [Medline].

  12. Busby JE, Low RK. Ureteroscopic treatment of renal calculi. Urol Clin North Am. 2004 Feb. 31(1):89-98. [Medline].

  13. Chaussy C, Fuchs G, Kahn R, et al. Transurethral ultrasonic ureterolithotripsy using a solid-wire probe. Urology. 1987 May. 29(5):531-2. [Medline].

  14. Denstedt JD, Clayman RV. Electrohydraulic lithotripsy of renal and ureteral calculi. J Urol. 1990 Jan. 143(1):13-7. [Medline].

  15. Denstedt JD, Eberwein PM, Singh RR. The Swiss Lithoclast: a new device for intracorporeal lithotripsy. J Urol. 1992 Sep. 148(3 Pt 2):1088-90. [Medline].

  16. Dretler SP, Watson G, Parrish JA, et al. Pulsed dye laser fragmentation of ureteral calculi: initial clinical experience. J Urol. 1987 Mar. 137(3):386-9. [Medline].

  17. Elbahnasy AM, Shalhav AL, Hoenig DM, et al. Lower caliceal stone clearance after shock wave lithotripsy or ureteroscopy: the impact of lower pole radiographic anatomy. J Urol. 1998 Mar. 159(3):676-82. [Medline].

  18. Erhard MJ, Bagley DH. Urologic applications of the holmium laser: preliminary experience. J Endourol. 1995 Oct. 9(5):383-6. [Medline].

  19. Fabrizio MD, Behari A, Bagley DH. Ureteroscopic management of intrarenal calculi. J Urol. 1998 Apr. 159(4):1139-43. [Medline].

  20. Goodfriend R. Disintegration of ureteral calculi by ultrasound. Urology. 1973 Mar. 1(3):260-3. [Medline].

  21. Grasso M. Experience with the holmium laser as an endoscopic lithotrite. Urology. 1996 Aug. 48(2):199-206. [Medline].

  22. Grasso M. Ureteropyeloscopic treatment of ureteral and intrarenal calculi. Urol Clin North Am. 2000 Nov. 27(4):623-31. [Medline].

  23. Grasso M, Beaghler M, Loisides P. The case for primary endoscopic management of upper urinary tract calculi: II. Cost and outcome assessment of 112 primary ureteral calculi. Urology. 1995 Mar. 45(3):372-6. [Medline].

  24. Grasso M, Ficazzola M. Retrograde ureteropyeloscopy for lower pole caliceal calculi. J Urol. 1999 Dec. 162(6):1904-8. [Medline].

  25. Grasso M, Loisides P, Beaghler M, et al. The case for primary endoscopic management of upper urinary tract calculi: I. A critical review of 121 extracorporeal shock-wave lithotripsy failures. Urology. 1995 Mar. 45(3):363-71. [Medline].

  26. Hofbauer J, Hobarth K, Marberger M. Lithoclast: new and inexpensive mode of intracorporeal lithotripsy. J Endourol. 1992. 6:429.

  27. Jeon SS, Hyun JH, Lee KS. A comparison of holmium:YAG laser with Lithoclast lithotripsy in ureteral calculi fragmentation. Int J Urol. 2005 Jun. 12(6):544-7. [Medline].

  28. Knudsen BE, Glickman RD, Stallman KJ, et al. Performance and safety of holmium: YAG laser optical fibers. J Endourol. 2005 Nov. 19(9):1092-7. [Medline].

  29. Leveillee RJ, Lobik L. Intracorporeal lithotripsy: which modality is best?. Curr Opin Urol. 2003 May. 13(3):249-53. [Medline].

  30. Raney AM. Electrohydraulic lithotripsy: experimental study and case reports with the stone disintegrator. J Urol. 1975 Mar. 113(3):345-7. [Medline].

  31. Weizer AZ, Springhart WP, Ekeruo WO, et al. Ureteroscopic management of renal calculi in anomalous kidneys. Urology. 2005 Feb. 65(2):265-9. [Medline].

 
Previous
Next
 
Staghorn renal calculus is noted on plain radiograph of the abdomen.
Intravenous pyelography defines a functioning kidney with a large branching intrarenal stone burden.
Treatment was based on percutaneous access and rigid endoscopic lithotripsy to clear the central stone burden with the hollow core ultrasonic lithotripter. On this image, a flexible nephroscope and holmium laser were also used to address portions of the stone burden inaccessible to the rigid equipment.
This is an endoscopic image of a holmium laser fiber fragmenting a stone burden.
Ureteroscopy and laser lithotripsy. Video courtesy of Dennis G Lusaya, MD, and Edgar V Lerma, MD.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.